| 000 | 01289 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250516172338.0 | ||
| 264 | 0 | _c20140106 | |
| 008 | 201401s 0 0 eng d | ||
| 022 | _a1535-5667 | ||
| 024 | 7 |
_a10.2967/jnumed.113.127829 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBasu, Sandip | |
| 245 | 0 | 0 |
_aShould grade of tracer uptake on somatostatin receptor-targeted imaging be the major determinant and break the barrier of histopathologic criteria for determining the suitability of Peptide receptor radionuclide therapy? _h[electronic resource] |
| 260 |
_bJournal of nuclear medicine : official publication, Society of Nuclear Medicine _cNov 2013 |
||
| 300 |
_a2018-9 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInternational Agencies |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xmethods |
| 650 | 0 | 4 |
_aNeuroendocrine Tumors _xradiotherapy |
| 650 | 0 | 4 | _aNuclear Energy |
| 650 | 0 | 4 |
_aRadiotherapy _xmethods |
| 650 | 0 | 4 |
_aReceptors, Peptide _xmetabolism |
| 650 | 0 | 4 | _aSocieties, Scientific |
| 773 | 0 |
_tJournal of nuclear medicine : official publication, Society of Nuclear Medicine _gvol. 54 _gno. 11 _gp. 2018-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2967/jnumed.113.127829 _zAvailable from publisher's website |
| 999 |
_c23121779 _d23121779 |
||